Previous research by Li et al. (2016) has reported that MSCs obtained from the bone marrow have the potential to treat ALI by suppressing inflammation by downregulating the TLR2 and 4/NF-κB pathways. The gene discussed is TLR2; the disease is acute respiratory distress syndrome.